Komori
Daiken Medical (7775) · PolicyRestated

Investing Retained Earnings in Promising Business Areas

First written in FY2017. 7 of 8 entries say "Restated". Latest entry: 2026-06-03.

8entries
10years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – 2026-06-032017: 120172018: 120182019: 120192020: 120202021: 120212022: 120222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies

135 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 224 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-06-03RestatedGeneral Meetings of Shareholders

    「We intend to invest retained earnings in promising business areas and increase corporate value by achieving greater profitability and growth, thereby expanding investment value and enabling further returns to shareholders.」

    The company continues its policy of investing retained earnings in promising business areas to improve profitability and growth, increase corporate value and enhance shareholder returns.
  2. FY2025RestatedAnnual report

    「We intend to invest retained earnings in promising business areas and increase corporate value by achieving greater profitability and growth, thereby expanding investment value and enabling further returns to shareholders.」

    内部留保を有望事業への投資に充て、利益性・成長性、企業価値、将来の利益還元につなげる方針を継続している。
  3. FY2022RestatedAnnual report

    「We intend to invest retained earnings in promising business areas and increase corporate value by achieving greater profitability and growth, thereby expanding investment value and enabling further returns to shareholders.」

    内部留保を有望事業への投資に充て、利益性・成長性、企業価値、将来の利益還元につなげる方針を継続している。
  4. FY2021RestatedAnnual report

    「We intend to invest retained earnings in promising business areas and increase corporate value by achieving greater profitability and growth, thereby expanding investment value and enabling further returns to shareholders.」

    内部留保を有望事業への投資に充て、利益性・成長性、企業価値、将来の利益還元につなげる方針を継続している。
  5. FY2020RestatedAnnual report

    「We intend to invest retained earnings in promising business areas and increase corporate value by achieving greater profitability and growth, thereby expanding investment value and enabling further returns to shareholders.」

    内部留保を有望事業への投資に充て、利益性・成長性、企業価値、将来の利益還元につなげる方針を継続している。
  6. FY2019RestatedAnnual report

    「We intend to invest retained earnings in promising business areas and increase corporate value by achieving greater profitability and growth, thereby expanding investment value and enabling further returns to shareholders.」

    内部留保を有望事業への投資に充て、利益性・成長性、企業価値、将来の利益還元につなげる方針を継続している。
  7. FY2018RestatedAnnual report

    「We intend to invest retained earnings in promising business areas and increase corporate value by achieving greater profitability and growth, thereby expanding investment value and enabling further returns to shareholders.」

    内部留保を有望事業への投資に充て、利益性・成長性、企業価値、将来の利益還元につなげる方針を継続している。
  8. FY2017First statedAnnual report

    「We intend to invest retained earnings in promising business areas and increase corporate value by achieving greater profitability and growth, thereby expanding investment value and enabling further returns to shareholders.」

    内部留保を有望事業分野への投資に充て、利益性・成長性、企業価値、投資価値、将来の利益還元につなげる方針を示している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Daiken Medical's next results are scheduled for 2026-10-30. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-06-03: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Investing Retained Earnings in Promising Business Areas | DAIKEN MEDICAL CO.,LTD. (7775) | Komori